Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GERN 
Geron Corporation (GERN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: GERN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.62
1 Year Target Price $3.62
| 4 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.41% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 807.03M USD | Price to earnings Ratio - | 1Y Target Price 3.62 |
Price to earnings Ratio - | 1Y Target Price 3.62 | ||
Volume (30-day avg) 9 | Beta 0.57 | 52 Weeks Range 1.09 - 4.50 | Updated Date 10/14/2025 |
52 Weeks Range 1.09 - 4.50 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -53.52% | Operating Margin (TTM) -25.4% |
Management Effectiveness
Return on Assets (TTM) -9.63% | Return on Equity (TTM) -31.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 614325560 | Price to Sales(TTM) 4.91 |
Enterprise Value 614325560 | Price to Sales(TTM) 4.91 | ||
Enterprise Value to Revenue 3.74 | Enterprise Value to EBITDA -9.06 | Shares Outstanding 638017073 | Shares Floating 534077712 |
Shares Outstanding 638017073 | Shares Floating 534077712 | ||
Percent Insiders 0.1 | Percent Institutions 81.95 |
Upturn AI SWOT
Geron Corporation
Company Overview
History and Background
Geron Corporation, founded in 1990, is a biotechnology company focused on developing first-in-class telomerase inhibitors to treat hematologic myeloid malignancies. Its primary focus has been on imetelstat, a telomerase inhibitor.
Core Business Areas
- Pharmaceutical Development: Focuses on the development and commercialization of imetelstat for hematologic malignancies, particularly myelodysplastic syndromes (MDS) and myelofibrosis (MF).
Leadership and Structure
The leadership team includes the CEO, John A. Scarlett, MD. The organizational structure is typical of a biotech company with distinct departments for research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Imetelstat: Imetelstat is a telomerase inhibitor being developed for the treatment of lower-risk myelodysplastic syndromes (LR-MDS) and relapsed/refractory myelofibrosis (r/r MF). It is currently awaiting FDA approval for LR-MDS. Competitors in MDS include drugs like Revlimid (Celgene/Bristol Myers Squibb) and Vidaza (Celgene/Bristol Myers Squibb).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Success depends on clinical trial outcomes and regulatory approvals.
Positioning
Geron is positioned as a leader in telomerase inhibition therapy. Its competitive advantage lies in its first-in-class telomerase inhibitor, imetelstat.
Total Addressable Market (TAM)
The total addressable market for MDS and myelofibrosis is estimated to be in the billions of dollars. Geron's position is dependent on successful commercialization of imetelstat in both indications.
Upturn SWOT Analysis
Strengths
- First-in-class telomerase inhibitor
- Strong clinical data for imetelstat in MDS and myelofibrosis
- Experienced management team
- Potential for significant market share
Weaknesses
- Reliance on a single product (imetelstat)
- High development costs
- Regulatory risks
- Commercialization risks
Opportunities
- Expansion of imetelstat into other hematologic malignancies
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- FDA approval for imetelstat
Threats
- Competition from existing therapies
- Clinical trial failures
- Regulatory setbacks
- Patent challenges
Competitors and Market Share
Key Competitors
- BMY
- MRTX
- NK
- CLVS
Competitive Landscape
Geron's advantages lie in its innovative telomerase inhibitor. Disadvantages include reliance on a single product and competition from established therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical development milestones and investor sentiment.
Future Projections: Future growth is dependent on the successful commercialization of imetelstat, with potential for significant revenue growth if approved and adopted.
Recent Initiatives: Recent strategic initiatives include progressing imetelstat through late-stage clinical trials and preparing for potential commercial launch.
Summary
Geron Corporation is a clinical-stage biopharmaceutical company focused on imetelstat, a telomerase inhibitor for hematologic malignancies. Its strength lies in the potential of imetelstat, however, it relies on a single product. Positive trial data is working well, but regulatory outcomes and competition remain risks. Geron must navigate the challenges of commercializing a new drug and face competition from established therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Geron Corporation website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Geron Corporation
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 1996-06-30 | CEO, President & Director Mr. Harout Semerjian | ||
Sector Healthcare | Industry Biotechnology | Full time employees 229 | Website https://www.geron.com |
Full time employees 229 | Website https://www.geron.com | ||
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.